SEC Comment Letter 0000000000-24-008949 to Insight Molecular Diagnostics Inc. (IMDX)
Insight Molecular Diagnostics Inc.
Date: Aug. 6, 2024 · CIK: 0001642380 · Accession: 0000000000-24-008949
AI Filing Summary & Sentiment
File numbers found in text: 333-281159
Letter
August 6, 2024 Joshua Riggs President and Chief Executive Officer Oncocyte Corporation 15 Cushing Irvine, California 92618 Re:Oncocyte Corporation Registration Statement on Form S-3 Filed August 1, 2024 File No. 333-281159 Dear Joshua Riggs: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Pace McCaskill, Esq.
Show Raw Text
August 6, 2024
Joshua Riggs
President and Chief Executive Officer
Oncocyte Corporation
15 Cushing
Irvine, California 92618
Re:Oncocyte Corporation
Registration Statement on Form S-3
Filed August 1, 2024
File No. 333-281159
Dear Joshua Riggs:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Pace McCaskill, Esq.